Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niskanen, L.
Right arrow Articles by Niklason, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niskanen, L.
Right arrow Articles by Niklason, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 24:2091-2096, 2001
© 2001 by the American Diabetes Association, Inc.

Pathophysiology/Complications
Original Article

Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy With an ACE Inhibitor Compared With a Diuretic/ß-Blocker–Based Treatment Regimen

A subanalysis of the Captopril Prevention Project

Leo Niskanen, MD, Thomas Hedner, MD, Lennart Hansson, MD, Jan Lanke, MD, Anders Niklason, MB and for the CAPPP study group

Department of Medicine, University of Kuopio, Kuopio, Finland

OBJECTIVE—The Captopril Prevention Project (CAPPP) evaluated the effects of an ACE inhibitor–based therapeutic regimen on cardiovascular mortality and morbidity in hypertension. One planned subanalysis of the CAPPP was to evaluate the outcome in the diabetic patient group.

RESEARCH DESIGN AND METHODS—In the CAPPP, 572 (4.9% of 10,985 hypertensive patients) had diabetes at baseline and were studied according to a prospective, randomized, open, blinded, end point trial design. Patients aged 25–66 years with diastolic blood pressure >=100 mmHg were included and randomized to receive either captopril or conventional antihypertensive treatment (diuretics and/or ß-blockers).

RESULTS—The primary end point, fatal and nonfatal myocardial infarction and stroke as well as other cardiovascular deaths, was markedly lower in the captopril than in the conventional therapy group (relative risk [RR] = 0.59; P = 0.018). Specifically, cardiovascular mortality, defined as fatal stroke and myocardial infarction, sudden death, and other cardiovascular death, tended to be lower in the captopril group (RR = 0.48; P = 0.084), and no difference was observed between the study groups for stroke (RR = 1.02; P = 0.96). Myocardial infarctions were less frequent in the captopril group than in the conventional therapy group (RR = 0.34; P = 0.002). Furthermore, total mortality was lower in the captopril as compared with the conventional therapy group (RR = 0.54; P = 0.034). Patients with impaired metabolic control seemed to benefit the most from ACE inhibitor–based therapy.

CONCLUSIONS—Captopril is superior to a diuretic/ß-blocker antihypertensive treatment regimen in preventing cardiovascular events in hypertensive diabetic patients, especially in those with metabolic decompensation.

Abbreviations: CAPPP, Captopril Prevention Project • CHF, congestive heart failure • IHD, ischemic heart disease • HOT, Hypertension Optimal Treatment • RR, relative risk • UKPDS, U.K. Prospective Diabetes Study • WHO, World Health Organization


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
C. Abaterusso, A. Lupo, V. Ortalda, V. De Biase, A. Pani, M. Muggeo, and G. Gambaro
Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1185 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. Osher and N. Stern
Diastolic Pressure in Type 2 Diabetes: Can target systolic pressure be reached without "diastolic hypotension"?
Diabetes Care, February 1, 2008; 31(Supplement_2): S249 - S254.
[Abstract] [Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
A. D. Naik, T. T. Issac, R. L. Street Jr, and M. E. Kunik
Understanding the Quality Chasm for Hypertension Control in Diabetes: A Structured Review of "Co-maneuvers" Used in Clinical Trials
J Am Board Fam Med, September 1, 2007; 20(5): 469 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]

Home page
 CirculationHome page
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Circulation, December 19, 2006; 114(25): 2850 - 2870.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Watanabe, T. Tagawa, K. Yamakawa, M. Shimabukuro, and S. Ueda
Inhibition of the Renin-Angiotensin System Prevents Free Fatty Acid-Induced Acute Endothelial Dysfunction in Humans
Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2376 - 2380.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
A. B. Rosen, M. B. Hamel, M. C. Weinstein, D. M. Cutler, A. M. Fendrick, and S. Vijan
Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes
Ann Intern Med, July 19, 2005; 143(2): 89 - 99.
[Abstract] [Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
N. P. Kopyt
Slowing Progression Along the Renal Disease Continuum
J Am Osteopath Assoc, April 1, 2005; 105(4): 207 - 215.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. S. Brooks and J. R. Sowers
Importance of Achieving Lower Blood Pressure in Hypertensive Patients With Diabetes
Hypertension, November 1, 2004; 44(5): 614 - 615.
[Full Text] [PDF]

Home page
 HypertensionHome page
G. L. Bakris, E. Gaxiola, F. H. Messerli, G. Mancia, S. Erdine, R. Cooper-DeHoff, C. J. Pepine, and for the INVEST Investigators
Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study
Hypertension, November 1, 2004; 44(5): 637 - 642.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Prasad and A. A. Quyyumi
Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome
Circulation, September 14, 2004; 110(11): 1507 - 1512.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, and L. Deferrari
Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S6 - 11.
[Abstract] [Full Text]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
S. Ross and M.-J. Macleod
Review: Hypertension in diabetes: a perspective from clinical pharmacology
The British Journal of Diabetes & Vascular Disease, July 1, 2003; 3(4): 252 - 256.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
R. Harris, K. Donahue, S. S. Rathore, P. Frame, S. H. Woolf, and K. N. Lohr
Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, February 4, 2003; 138(3): 215 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. D. Mooradian
Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines
Arch Intern Med, January 13, 2003; 163(1): 33 - 40.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. R. Sowers and S. Haffner
Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
Hypertension, December 1, 2002; 40(6): 781 - 788.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Egger
Is ACE Inhibitor the Best First-Line Agent for Diabetes With Hypertension?
Diabetes Care, August 1, 2002; 25(8): 1488 - 1488.
[Full Text]

Home page
 Diabetes CareHome page
L. Niskanen, T. Hedner, L. Hansson, J. Lanke, and A. Niklason
ACE Inhibitor as One of Several Possible First-Line Agents Is Reasonable for Diabetic Patients With Hypertension
Diabetes Care, August 1, 2002; 25(8): 1488 - 1489.
[Full Text]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. D Walker
Review: Angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in diabetic renal disease
The British Journal of Diabetes & Vascular Disease, March 1, 2002; 2(2): 81 - 84.
[Abstract] [PDF]

Home page
 Journal Watch CardiologyHome page
ACE Inhibitors for Hypertensive Diabetics
Journal Watch Cardiology, February 8, 2002; 2002(208): 5 - 5.
[Full Text]

Home page
 JWatch GeneralHome page
Another Plug for ACE Inhibitors in Hypertensive Diabetic Patients
Journal Watch (General), December 18, 2001; 2001(1218): 1 - 1.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.